Fernando
Lecanda Cordero
Profesional Investigador
Instituto de Salud Carlos III
Madrid, EspañaPublicacións en colaboración con investigadores/as de Instituto de Salud Carlos III (3)
2023
-
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
Nature Communications, Vol. 14, Núm. 1
2021
-
FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted
Journal of Hepatology, Vol. 75, Núm. 2, pp. 363-376
2020
-
Sarcoma treatment in the era of molecular medicine
EMBO Molecular Medicine, Vol. 12, Núm. 11